Sign In
Buy MCRB
$7.17
-0.160 (-2.18%)
At Close: Jun 03, 2026
Earnings Preview: Seres Therapeutics (MCRB) Q2 Earnings Expected to Decline
04:33pm, Tuesday, 28'th Jul 2020
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recap: Seres Therapeutics Q2 Earnings
01:41pm, Tuesday, 28'th Jul 2020
Shares of Seres Therapeutics (NASDAQ:MCRB) fell 6.4% after the company reported Q2 results.Quarterly Results Earnings per share decreased 16.67% over the past year to ($0.28), which missed the estimat
Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
11:00am, Tuesday, 28'th Jul 2020
Topline data from SER-109 Phase 3 study in recurrent C. difficile infection expected in August 2020; pipeline of other promising candidates advancing.
How are the Stock Market, Earthquakes, and Disease Related?
12:10am, Tuesday, 28'th Jul 2020
Predicting the spread of infections using time series data, with techniques traditionally applied to model financial trends
Debêntures: aprenda como investir nesses títulos de renda fixa
02:32am, Monday, 27'th Jul 2020
As debêntures títulos de renda fixa de crédito privado que normalmente possuem maior rentabilidade. Clique e saiba como investir em debêntures.
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
12:00am, Sunday, 26'th Jul 2020
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
Chute «historique» des embauches au second trimestre en France
09:23am, Wednesday, 22'nd Jul 2020
Après plusieurs mois de baisse spectaculaire, les embauches se reprennent en mai et juin. Le bilan du trimestre reste inquiétant.
En quoi va consister l'aide à l'embauche des jeunes promise par le gouvernement ?
09:16am, Tuesday, 21'st Jul 2020
Jusqu'ici, la piste privilégiée était une « exonération de charges » salariales mais il n'est pas exclu que l'aide prenne finalement la forme d'une prime. En baissant le coût du travail, l'ex
Apesar da Selic em piso histórico, gestoras de multimercados resistem a reduzir famosa taxa "2% com 20%"
08:24pm, Monday, 20'th Jul 2020
Levantamento revela que apenas dois de 76 fundos reduziram a cobrança durante o primeiro semestre de 2020
Com 920 mil novos cotistas no 1º semestre, fundos de renda fixa perdem para o CDI e cobram até 1,75% ao ano
02:00pm, Sunday, 19'th Jul 2020
Entre os 20 fundos de renda fixa com maior entrada de cotistas entre janeiro e junho, 15 perderam para o CDI, mostra levantamento do InfoMoney
California Department of Insurance Investigation Leads to $5.5M Settlement
02:56pm, Thursday, 16'th Jul 2020
A settlement has been announced between Libre by Nexus Inc. in which it will cease transacting immigration bonds in the California, phase out the use of
Regulatory News: DEINOVE (Paris:ALDEI) (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation platform to develop inno
RPS Capital vê investidor maduro e oferece filosofia diferente | InfoMoney
06:01pm, Tuesday, 14'th Jul 2020
RPS Capital: a Gestora investida pelos principais Family Offices do país abre ao varejo fundos de ações descorrelacionados para diferentes
Seres Therapeutics (NASDAQ:MCRB) Upgraded to “Buy” by Zacks Investment Research
05:32am, Tuesday, 14'th Jul 2020
Seres Therapeutics (NASDAQ:MCRB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday, Zacks.com reports. The brokerage current
ICIS gibt die Übernahme von Chemical Data (CDI) bekannt
08:04am, Monday, 13'th Jul 2020
ICIS, Teil von RELX, gab heute die Übernahme von Chemical Data, LLC (CDI), einem führenden Anbieter von US-Preis-Benchmarks für petrochemische Produkte, Marktanalysen und vorausschauende Analysen m
